MorphoSys AG (MOR) Stock News
NASDAQ:MOR - Nasdaq - US6177602025 - ADR - Currency: USD
MOR Latest News, Press Relases and Analysis
Morpheus Launches $20 Million In Rewards For AI Compute Providers
Morpheus, a decentralized platform for deploying AI-driven “Smart Agents,” has launched a $20 million reward program for compute providers.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI on Behalf of Shareholders
3 Global Stocks to Buy to Escape the Volatility on Wall Street
Discover three top global stocks as a smart hedge against Wall Street volatility, offering diversification and resilience in uncertain times.
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates SILK, MOR, AFBI, MGOL on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
MorphoSys Announces Voluntary Delisting from the Nasdaq Global Market
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates DM, SHCR, MOR, ALE on Behalf of Shareholders
Kuehn Law Encourages DM, SHCR, MOR, and ALE Investors to Contact Law Firm
/PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating potential claims related to the below-listed proposed mergers. Kuehn Law...
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates ALLG, MOR, BEST, MGOL on Behalf of Shareholders
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BEST, MOR, HCP, SQSP on Behalf of Shareholders
/PRNewswire/ -- Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws...
MOR STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of MorphoSys AG Is Fair to Shareholders
MOR Stock Earnings: MorphoSys Misses EPS, Misses Revenue for Q1 2024
MOR stock results show that MorphoSys missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.
MorphoSys AG Reports First Quarter 2024 Financial Results
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth.
Exit Now! 3 Biotech Stocks to Sell in February 2024
These biotech stocks to sell represent incredibly risky bets, amidst the sector's volatility and looming economic unpredictability.
JMP cuts Incyte to market perform, cites need for acquisition (NASDAQ:INCY)
JMP has downgraded Incyte (INCY) to market perform, asserting that the company will likely need an acquisition to ensure its current cash flow. In its note, the
Mentions: INCY
MorphoSys ADRs gain after definitive merger agreement with Novartis disclosed (NASDAQ:MOR)
Shares of MorphoSys (MOR) surged 4.5% after Novartis (NVS) merger agreement was revealed, debunking a previous report on the deal.
Mentions: NVS
Morphosys ADRs gain after definitive merger agreement with Novartis disclosed
Shares of MorphoSys (MOR) surged 4.5% after Novartis (NVS) merger agreement was revealed, debunking a previous report on the deal.
Mentions: NVS
MorphoSys drops amid speculation Novartis could walk from deal (NASDAQ:MOR)
Speculation about Novartis potentially exiting a deal with MorphoSys leads to a 3% drop in ADRs; however, both companies deny the report's accuracy.
Mentions: NVS
MorphoSys ADRs drop amid speculation Novartis could walk from deal (NASDAQ:MOR)
Speculation about Novartis potentially exiting a deal with MorphoSys leads to a 3% drop in ADRs; however, both companies deny the report's accuracy.
Mentions: NVS
MorphoSys ADRs drop amid speculation Novartis could walk from deal
Speculation about Novartis potentially exiting a deal with MorphoSys leads to a 3% drop in ADRs; however, both companies deny the report's accuracy.
Mentions: NVS
Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion
Novartis will add to its cancer treatment pipeline with via the German biotech.
Incyte buys global rights for tafasitamab from MorphoSys (NASDAQ:INCY)
Incyte (INCY) has bought the global commercialization rights to tafasitamab, also known as Monjuvi, from partner MorphoSys (MOR) for $25M. Read more here.